Hot on DailyFinance:

See More Stories
Feed

U.S. Stock Futures Lower; Nokia Shares Slide on Microsoft Deal

U.S. stock futures are lower this morning. Futures for the Dow Jones Industrial Average dropped 39 points to 12,155, while those for the S&P 500 index declined 6.1 points to 1,313. Futures for the Nasdaq 100 index lost 7.75 points to 2,354.

Shares of Nokia (NOK) dropped in pre-market trading as the company unveiled partnership with Microsoft (MSFT).

Negative sentiment ruled the European markets today. While STOXX Europe 600 Index has dropped 0.42%, London's FTSE 100 Index moved down 0.27%.

Continue reading U.S. Stock Futures Lower; Nokia Shares Slide on Microsoft Deal

Eli Lilly Likely to Remain Limp

Eli Lilly logoAlthough short-term news may seem bright for Eli Lilly & Co. (LLY), the broader picture for the company looks flat. Having dropped from an average share price in the $53 range over two years ago, to a current average share value hovering near $35, investors are signaling that the long range forecast for Lilly is unexciting at best.

It appears that Lilly shall be buoyed in the near term by the recent FDA approval of testosterone replacement therapy Axiron for sale in the U.S. Lilly purchased rights to Axiron from Australian firm, Acrux for an initial payment of $50 million plus $3 million based on the transfer of manufacturing assets.

Continue reading Eli Lilly Likely to Remain Limp

Are Dividend Rates About to Drop 29%?

Is it time to dump dividend stocks before the Bush tax cuts expire? In 2001 and 2003 Bush, passed several tax relief bills that will automatically expire at the end of 2010. Obama campaigned against the tax relief packages and many Americans may be facing a huge tax increase as the package expires.

Dividend taxation is of particular concern to investors. Under the relief packages, dividends taxes were cut to 15%, but if the package expires, dividends may be taxed as ordinary income at levels up to 39.6%.

Continue reading Are Dividend Rates About to Drop 29%?

Wall Street Ignoring Big Pharma -- Should You?

In its weekend edition, Barron's Andrew Bary wonders whether Big Pharma's punishment on Wall Street has gone too far. The sector has fallen out of favor with Wall Street and now has one of the lowest price/earnings ratios of any major sector of the stock market, Bary writes.

Investors are staying away from the large pharmaceutical companies ahead of their looming patent cliff, when blockbuster drugs like Lipitor, Plavix and Singulair lose patent protection and lose most of the sales from these drugs to generics. Investors also fear the companies don't have enough new drugs in the pipeline to make up for the lost sales, which could mean big hits to earnings.

But when the Street writes off one of the world's most important industries and with valuations at all-time lows, investors ought to take notice, Bary says. Especially when the average dividend yield of the big drugmakers is 4.8%.

Continue reading Wall Street Ignoring Big Pharma -- Should You?

Three Famous Dividend All-Stars

Great dividend picks are easier to find than you think. Retirees looking for safe places to stash their cash are already familiar with many blue chips that have hefty yields. It's just that when investors stop at the grocery store or pay their phone bill, they aren't thinking about how the big brands they're doing business with are actually good dividend payers.

Here are three of America's best know public corporations with yields that are about twice what 10-year Treasuries pay. These low-risk blue chips are some of the most famous high-yield dividend stocks out there.

Continue reading Three Famous Dividend All-Stars

Before the Bell: Futures Lower as Goldman Shockwaves Continue

U.S. stock futures fell Monday, indicating that stocks could retreat at the open, as Wall Street remained shaken by SEC the fraud allegations against Goldman Sachs. Investors will focus on more corporate results, including from Citigroup, and await some economic data.

On Friday, Wall Street reeled after hearing the Securities and Exchange Commission brought civil fraud charges against Goldman Sachs Group Inc. (GS) in relation to subprime securities. Goldman defrauded investors, the charges say, by not telling investors material information, specifically that the CDO it was selling had been deliberately constructed out of residential mortgages backed securities ikely to become worthless. Goldman Sachs shares dropped nearly 13% on Friday.

Continue reading Before the Bell: Futures Lower as Goldman Shockwaves Continue

$75 Million in Drugs Stolen from Eli Lilly Warehouse

Eli Lilly (LLY) announced Wednesday that burglars broke into a Connecticut-based warehouse over the weekend and stole roughly $75 million in prescription drugs. According to police, the break-in happened either late Saturday or early Sunday. According to LLY, "dozens of pallets" of antidepressants were stolen, including Prozac, Cymbalta, Zyprexa (an anti-psychotic), and other medicines. The police called the theft a "well-planned event."

The company stated that it is working with the U.S. FDA Office of Criminal Investigations and other law enforcement officials. LLY's senior vice president of global equity noted that the company has "taken quick and appropriate actions to ensure the safety of our medicines." The company added that the "U.S. pharmaceutical distribution system is tightly controlled and monitored, making it extremely difficult for stolen product to make it to patients through legitimate channels."

Continue reading $75 Million in Drugs Stolen from Eli Lilly Warehouse

Biogen Idec names new chairman, announces positive drug test results

Biogen Idec (BIIB) has made a bit of news the past two days, starting with Thursday's news that William Young is the company's new chairman of the board. BIIB's Bruce Ross will complete his term as director and will step down from the board at BIIB's 2010 shareholder meeting. William Young will take over effective January 1, 2010. Young is a veteran of the biotech industry, as he served with Monogram Biosciences, Genentech (where he was CEO), and Eli Lilly.

Ross noted, "I am pleased the Board has selected Bill Young as Biogen Idec's new Chairman. He is an experienced biotechnology and pharmaceutical industry executive with an extensive understanding of Biogen Ides, given his 12 years of service as a director of the company."

Continue reading Biogen Idec names new chairman, announces positive drug test results

Serious Money: Fortune's 25 leaders, 18 remain

This is the third screening to find value among Fortune's 25 corporate world leaders that have demonstrated an ability to regenerate themselves from within. The list has been cut to 18 and will be cut further here.

The methodology of using basic stock data points to identify potential value investments only sets the stage for success -- it assures nothing. While it is true that paying less is better than paying more and getting a higher yield is better than less, this gives you a scant picture of what is in people's hearts and minds, and that is harder to judge. Like the weather, no matter the predictions, you may not find out it is raining until you are standing in it. Regardless, it should be advantageous to start with good stock (pun intended) before you take to whittlin', and that we have.

Continue reading Serious Money: Fortune's 25 leaders, 18 remain

Serious Money: Fortune's 25 leaders, now 20

Yesterday I started a review of 25 companies that Fortune deemed most successful according to their peers in developing quality leadership. Today I review the remaining 20, searching to find the ones that might be worth investing in.

Price-to-book (from 11/27/09) was used as the first value screen. The theory being from a value investor's perspective that buying for a price at or near the break-up value of the company provides downside protection. Of course that is easier said than done.

Continue reading Serious Money: Fortune's 25 leaders, now 20

Serious Money: Fortune's 25 leaders among leaders

The recent issue of Fortune magazine discusses how the best of the best train, guide and nurture top managers to become the leaders that will propel their corporations successfully forward. They list the top 25 companies, which I have used as the basis of a new review to see how they would fair against common metric screens.

In the past few months, many articles have posited that large-cap stocks should excel in the coming year based on their lagging the market behind smaller, more volatile stocks flying out of the March lows. I do not believe this is universally true. Plenty of large-cap stocks did well, such as Anadarko Petroleum (APC), Apple (AAPL) and Google (GOOG), while many small caps went nowhere. Even among the large caps included in Fortune's "Leadership 25," some have doubled.

Continue reading Serious Money: Fortune's 25 leaders among leaders

Cramer on BloggingStocks: Sanofi has lots of upside catalysts

TheStreet.com's Jim Cramer says it looks like the patent worries aren't so dire after all.

Now that we see that health care reform is not going to bring price caps or socialization of medicine, we are beginning to see some real expansion in the drug stocks, including Merck (MRK) (Cramer's Take), Bristol-Myers (BMY) (Cramer's Take) and Lilly (LLY) (Cramer's Take). But there is one drug stock that is continually met with skepticism -- Sanofi Aventis (SNY) (Cramer's Take), the French vaccine and pharmaceutical maker run by Christian Viehbacher. The resistance is obvious, as his biggest two drugs are coming off patent very soon, and his hope is that by 2013 the company might again reach 2008 levels.

Sounds like there's no reason to buy this one. Sounds like its 4% dividend isn't safe.

Continue reading Cramer on BloggingStocks: Sanofi has lots of upside catalysts

Lilly's stock meanders, but remains a Buy

Eli Lilly & Co. (NYSE: LLY) stock has unexpectedly meandered since the June 8, 2009 Buy recommendation at a price of $34.10, but the aforementioned probably represents selected investor jitters about the likely, federal health care reform legislation.

Ignore those jitters. The major components of health care reform have not been determined as of September 30, 2009, but the pharma calculation remains the same as it was in June. The legislation will be net-positive for major pharmaceutical companies, under the thesis that there will be 30-45 million more U.S. residents regularly - as opposed to sporadically - accessing health care services over the next decade, not including population growth.

Continue reading Lilly's stock meanders, but remains a Buy

Seven dividend elites: 100 years of dividends

"While companies have been cutting dividends at an historic pace over the last 24 months, the fact is that there are still quality companies with long histories of paying dividends that represent good long-term investments," says Chuck Carlson, a specialist in companies offering dividend reinvestment plans.

In his top-notch The DRIP Investor he says, "The seven stocks featured here have each been paying a dividend for over 100 years, have raised their dividend annually for at least the last quarter century and offer direct-purchase plans.

Continue reading Seven dividend elites: 100 years of dividends

Options Update: DuPont and Eli Lilly calls active on dividend play

DuPont (NYSE: DD) closed at $32.57. August 11 DD options were active on volume of 349,770 contracts into today's ex-dividend. DD August option implied volatility of 33; September is at 35; below its 26-week average 43 according to Track Data, suggesting decreasing price movement.

Eli Lilly (NYSE: LLY) closed at $33.18. LLY goes ex dividend today with a 49 cents dividend. On August 11 LLY options were active on volume of 28,953 contracts. LLY August option implied volatility is at 28, September is at 27; below its 26-week average of 31, suggesting decreasing price movement.

Options Update: Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com

Next Page »

Symbol Lookup
IndexesChangePrice
DJIA+6.5112,890.46
NASDAQ+11.372,927.23
S&P 500+1.991,351.95

Last updated: February 10, 2012: 02:57 AM

Hot Stocks

General Electric

19.13-0.11(-0.57)

Alcoa

10.64-0.03(-0.28)

Apple Inc

493.17+16.49(+3.46)

Google Inc 'A'

611.46+1.61(+0.26)

Bank of America

8.18+0.05(+0.62)

Wal-Mart Stores

61.96+0.34(+0.55)

Exxon Mobil Corp

84.88-0.44(-0.52)

Ford

12.69-0.15(-1.17)

Citigroup

33.66-0.57(-1.67)

IBM

193.13+0.18(+0.09)

Yahoo

16.00+0.22(+1.39)

Starbucks

49.20+0.48(+0.99)

Microsoft

30.77+0.11(+0.36)

Home Depot

45.27+0.10(+0.22)

DailyFinance Headlines

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance

Page Loaded in 1328860650060 ms.